DOCSLIB.ORG

Open Access Version If You Believe That This Document Breaches Copyright Please Contact Us Providing Details and We Will Investigate Your Claim

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Open Access Version If You Believe That This Document Breaches Copyright Please Contact Us Providing Details and We Will Investigate Your Claim University of Southern Denmark Withdrawal of antihypertensive drugs in older people Reeve, Emily; Jordan, Vanessa; Thompson, Wade; Sawan, Mouna; Todd, Adam; Gammie, Todd M; Hopper, Ingrid; Hilmer, Sarah N; Gnjidic, Danijela Published in: The Cochrane database of systematic reviews DOI: 10.1002/14651858.CD012572.pub2 Publication date: 2020 Document version: Final published version Citation for pulished version (APA): Reeve, E., Jordan, V., Thompson, W., Sawan, M., Todd, A., Gammie, T. M., Hopper, I., Hilmer, S. N., & Gnjidic, D. (2020). Withdrawal of antihypertensive drugs in older people. The Cochrane database of systematic reviews, 2020(6), [CD012572]. https://doi.org/10.1002/14651858.CD012572.pub2 Go to publication entry in University of Southern Denmark's Research Portal Terms of use This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply: • You may download this work for personal use only. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying this open access version If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to [email protected] Download date: 25. Sep. 2021 Cochrane Library Cochrane Database of Systematic Reviews Withdrawal of antihypertensive drugs in older people (Review) Reeve E, Jordan V, Thompson W, Sawan M, Todd A, Gammie TM, Hopper I, Hilmer SN, Gnjidic D Reeve E, Jordan V, Thompson W, Sawan M, Todd A, Gammie TM, Hopper I, Hilmer SN, Gnjidic D. Withdrawal of antihypertensive drugs in older people. Cochrane Database of Systematic Reviews 2020, Issue 6. Art. No.: CD012572. DOI: 10.1002/14651858.CD012572.pub2. www.cochranelibrary.com Withdrawal of antihypertensive drugs in older people (Review) Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Cochrane Trusted evidence. Informed decisions. Library Better health. Cochrane Database of Systematic Reviews T A B L E O F C O N T E N T S HEADER......................................................................................................................................................................................................... 1 ABSTRACT..................................................................................................................................................................................................... 1 PLAIN LANGUAGE SUMMARY....................................................................................................................................................................... 2 SUMMARY OF FINDINGS.............................................................................................................................................................................. 4 BACKGROUND.............................................................................................................................................................................................. 7 OBJECTIVES.................................................................................................................................................................................................. 7 METHODS..................................................................................................................................................................................................... 7 RESULTS........................................................................................................................................................................................................ 10 Figure 1.................................................................................................................................................................................................. 11 Figure 2.................................................................................................................................................................................................. 13 Figure 3.................................................................................................................................................................................................. 14 Figure 4.................................................................................................................................................................................................. 16 Figure 5.................................................................................................................................................................................................. 17 Figure 6.................................................................................................................................................................................................. 18 DISCUSSION.................................................................................................................................................................................................. 19 AUTHORS' CONCLUSIONS........................................................................................................................................................................... 21 ACKNOWLEDGEMENTS................................................................................................................................................................................ 22 REFERENCES................................................................................................................................................................................................ 23 CHARACTERISTICS OF STUDIES.................................................................................................................................................................. 27 DATA AND ANALYSES.................................................................................................................................................................................... 45 Analysis 1.1. Comparison 1: Discontinuation by no treatment/placebo of antihypertensives vs Continuation, Outcome 1: All- 47 cause mortality...................................................................................................................................................................................... Analysis 1.2. Comparison 1: Discontinuation by no treatment/placebo of antihypertensives vs Continuation, Outcome 2: 47 Cardiovascular mortality...................................................................................................................................................................... Analysis 1.3. Comparison 1: Discontinuation by no treatment/placebo of antihypertensives vs Continuation, Outcome 3: 47 Myocardial infarction (fatal and nonfatal)........................................................................................................................................... Analysis 1.4. Comparison 1: Discontinuation by no treatment/placebo of antihypertensives vs Continuation, Outcome 4: 48 Systolic blood pressure........................................................................................................................................................................ Analysis 1.5. Comparison 1: Discontinuation by no treatment/placebo of antihypertensives vs Continuation, Outcome 5: 48 Diastolic blood pressure....................................................................................................................................................................... Analysis 1.6. Comparison 1: Discontinuation by no treatment/placebo of antihypertensives vs Continuation, Outcome 6: 48 Hospitalisation...................................................................................................................................................................................... Analysis 1.7. Comparison 1: Discontinuation by no treatment/placebo of antihypertensives vs Continuation, Outcome 7: Stroke 49 (fatal + nonfatal + TIA).......................................................................................................................................................................... Analysis 1.8. Comparison 1: Discontinuation by no treatment/placebo of antihypertensives vs Continuation, Outcome 8: Sucess 49 rate - withdrawal/resumption due to hypertension or other clinical reason.................................................................................... Analysis 1.9. Comparison 1: Discontinuation by no treatment/placebo of antihypertensives vs Continuation, Outcome 9: Quality 49 of life...................................................................................................................................................................................................... Analysis 1.10. Comparison 1: Discontinuation by no treatment/placebo of antihypertensives vs Continuation, Outcome 10: 50 Systolic blood pressure subgrouped on duration.............................................................................................................................. Analysis 1.11. Comparison 1: Discontinuation by no treatment/placebo of antihypertensives vs Continuation, Outcome 11: 50 Systolic blood pressure subgrouped on drug type...........................................................................................................................
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • WO 2011/089216 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date t 28 July 2011 (28.07.2011) WO 2011/089216 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/48 (2006.01) C07K 1/13 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 1/1 07 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/050821 HN, HR, HU, ID, J , IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 2 1 January 201 1 (21 .01 .201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1015 1465. 1 22 January 2010 (22.01 .2010) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): AS- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, CENDIS PHARMA AS [DK/DK]; Tuborg Boulevard TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 12, DK-2900 Hellerup (DK).
    [Show full text]
  • Multimedia Appendix 1. Search Strategy Developed for Medline Via Ovid to Identify Existing Systematics Review. Concept 1: BP
    Multimedia Appendix 1. Search strategy developed for Medline via Ovid to identify existing systematics review. Concept 1: BP lowering regimens 1 exp antihypertensive agents/ 2 (antihypertensive$ adj (agent$ or drug)).tw. 3 exp thiazides/ 4 (chlorothiazide or benzothiadiazine or bendroflumethiazide or cyclopenthiazide or metolazone or xipamide or hydrochlorothiazide or hydroflumethiazide or methyclothiazide or polythiazide or trichlormethiazide or thiazide?).tw. 5 (chlorthalidone or chlortalidone or phthalamudine or chlorphthalidolone or oxodolin or thalitone or hygroton or indapamide or metindamide).tw. 6 ((loop or ceiling) adj diuretic?).tw. 7 (bumetanide or furosemide or torasemide).tw. 8 exp sodium potassium chloride symporter inhibitors/ 9 (eplerenone or amiloride or spironolactone or triamterene).tw. 10 or/1-9 11 exp angiotensin-converting enzyme inhibitors/ 12 ((angiotensin$ or kininase ii or dipeptidyl$) adj3 (convert$ or enzyme or inhibit$ or recept$)).tw. 13 (ace adj3 inhibit$).tw. 14 acei.tw. 15 exp enalapril/ 16 (alacepril or altiopril or benazepril or captopril or ceronapril or cilazapril or delapril or enalapril or fosinopril or idapril or imidapril or lisinopril or moexipril or moveltipril or pentopril or perindopril or quinapril or ramipril or spirapril or temocapril or trandolapril or zofenopril or teprotide).tw. 17 or/11-16 18 exp Angiotensin II Type 1 Receptor Blockers/ 19 (angiotensin$ adj4 receptor$ adj3 (antagon$ or block$)).tw. 20 exp losartan/ 21 (KT3-671 or candesartan or eprosartan or irbesartan or losartan or
    [Show full text]
  • Příloha K Vyhlášce Č. 57/1997 Sb. Léčivé Přípravky Plně Hrazené Ze
    Příloha k vyhlášce č. 57/1997 Sb. Léčivé přípravky plně hrazené ze zdravotního pojištění a výše úhrad jednotlivých léčivých látek ODDÍL A Léčivé přípravky plně hrazené ze zdravotního pojištění jsou v seznamu léčivých přípravků plně hrazených ze zdravotního pojištění a v přehledu jednotlivých léčivých látek s výší jejich úhrad (dále jen „seznam“) označeny jejich kódem a názvem s uvedením lékové formy a velikosti balení. Výše úhrady jednotlivých léčivých látek v korunách za uvedené jednotkové množství těchto léčivých látek je stanovena v sedmém sloupci příslušných řádků seznamu. V seznamu mají použité zkratky tento význam a) způsob podání (aplikace) inhal. inhalační aplikační formy (spraye, prášky a roztoky k inhalaci) intraderm. aplikační cesta některých alergenů (nitrokožně) lok. lokální (zevní) aplikační formy parent. injekční aplikační formy (injekce, suché injekce, infúze) p.o. perorální aplikační formy (tablety, tobolky, dražé, potahované tablety) p.rect. rektální aplikační formy PRICK test k diagnostice subkut. aplikační cesta některých alergenů sublng. perorální aplikační formy pod jazyk (apikace do dutiny ústní) transd. transdermální (kožní) aplikační formy (náplasti) vag. vaginální (poševní) aplikační formy b) lékové formy LF lékové formy aer aerosol aer dos aerosol s dávkovačem cap kapsle, tobolka cap inh kapsle inhalační (inhaleta) cap ret kapsle retardovaná crm krém crm fett krém mastný crm vag krém vaginální drg dražé drg ret dražé retardované emp náplast enm enema, klyzma foa pěna gel gel gel oph gel oční gel vag gel vaginální
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0266836A1 Buhlmayer Et Al
    US 2004O266836A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0266836A1 Buhlmayer et al. (43) Pub. Date: Dec. 30, 2004 (54) ORGANIC COMPOUNDS Related U.S. Application Data (76) Inventors: Peter Buhlmayer, Arlesheim (CH); (60) Provisional application No. 60/330,337, filed on Oct. Randy Lee Webb, Flemington, NJ 18, 2001. (US)US Publication Classification Correspondence Address: (51) Int. Cl." ..................... A61K 31/455; CO7D 213/46; NOVARTS CO7D 211/82 CORPORATE INTELLECTUAL PROPERTY (52) U.S. Cl 514/355; 54.6/315 ONE HEALTH PLAZA 430/2 Oa - 1 - O - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - s EAST HANOVER, NJ 07936-1080 (US) (57) ABSTRACT The invention relates to a salt formed of at least one (21) Appl. No.: 10/493,040 AT-receptor antagonist having at least one acidic center and of at least one cardiovascular ingredient having at least one (22) PCT Filed: Oct. 17, 2002 basic center that can be used for treating cardiovascular diseases and conditions, their prophylaxis or delay of pro (86) PCT No.: PCT/EP02/11652 gression. US 2004/0266836 A1 Dec. 30, 2004 ORGANIC COMPOUNDS 0007. The term “basic center” whenever referred hereinto means a functional group able to gain a proton, for example, 0001. This invention relates to salts formed of an AT the basic amino function in e.g. alkylamines, Such as ??, or receptor antagonist and a cardiovascular ingredient, phar any basic heterocycles, Such as pyridines, pyrazines, or maceutical compositions thereof and methods of using Said piperidines. Salts to treat patients Suffering from cardiovascular diseases and related conditions. 0008. The term “patient” whenever referred to herein 0002.
    [Show full text]
  • Supplemental Data
    DMD #48819 Supplemental Data Title: Application of Hybrid Approach Based on Empirical and Physiological Concept for Predicting Pharmacokinetics in Humans -Usefulness of Exponent on Prospective Evaluation of Predictability- Authors: Hiroyuki Sayama, Hiroshi Komura, Motohiro Kogayu Journal Title: Drug Metabolism and Disposition 1 DMD #48819 Supplemental Table 1 In vitro and in vivo data for allometric scaling of CL and Vss fup RB in vitro CLint (mL/min/kg) in vivo CL (mL/min/kg) in vivo Vss (mL/kg) Refference Human Human Human Dog Monkey Rabbit Rat Mouse Human Dog Monkey Rabbit Rat Mouse Human Dog Monkey Rabbit Rat Mouse Acivicin -- -- -- -- -- -- -- -- -- -- -- -- -- -- 580 500 600 -- 650 930 63 Alfentanil -- -- -- -- -- -- -- -- -- -- -- -- -- -- 800 953 -- 1069 975 -- 8 Amiodarone -- -- -- -- -- -- -- -- -- -- -- -- -- -- 66000 4600 5110 -- 72300 -- 23 Amlodipine -- -- -- -- -- -- -- -- -- -- -- -- -- -- 21000 25000 -- -- 32000 27000 101 Amphotericin B -- -- -- -- -- -- -- -- -- -- -- -- -- -- 4011 5025 -- 1855 2300 3121 85 Amsacrine -- -- -- -- -- -- -- -- -- -- -- -- -- -- 1560 2800 -- 1700 4500 7420 80 Antipyrine 1 1 0.28 3.95 -- 4.07 1.58 -- 0.62 a 8.18 a -- 7.32 a 3.53 a -- 584 a 738 a -- 903 a 657 a 720 5, 6, 12, 52, 76, 91, 118 Biperiden -- -- -- -- -- -- -- -- -- -- -- -- -- -- 6200 9500 3600 19300 14000 -- 23, 70 Bosentan -- -- 0.68 0.87 -- 15.89 5.71 7.91 2.00 1.3 -- 72 38.1 31.43 -- -- -- -- -- -- 49, 52 Caffeine 0.96 1 0.40 0.83 -- 1.18 2.55 -- 1.32 a 1.83 a -- 5.03 a 5.02 a -- 614 a 887 a 830 508 a 763 a 760 9, 10, 11, 17,
    [Show full text]
  • SUPPLEMENTARY MATERIAL 1: Search Strategy
    SUPPLEMENTARY MATERIAL 1: Search Strategy Medline search strategy 1. exp basal ganglia hemorrhage/ or intracranial hemorrhages/ or cerebral hemorrhage/ or intracranial hemorrhage, hypertensive/ or cerebrovascular disorders/ 2. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or pon$ or lentiform$ or brainstem or cortic$ or cortex$ or subcortic$ or subcortex$) adj5 (h?emorrhag$ or h?ematoma$ or bleed$)).tw 3. ((hemorrhag$ or haemorrhag$) adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw 4. (ICH or ICHs or PICH or PICHs).tw 5. 1 or 2 or 3 or 4 6. exp blood pressure/ 7. exp hypertension/ 8. (blood pressure or bloodpressure).tw 9. ((bp or blood pressure) adj5 (lowering or reduc$)).tw 10. ((strict$ or target$ or tight$ or intens$ or below) adj3 (blood pressure or systolic or diastolic or bp or level$)).tw 11. (hypertension or hypertensive).tw 12. ((manage$ or monitor$) adj3 (hypertension or blood pressure)).tw 13. ((intense or intensive or aggressive or accelerated or profound or radical or severe) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 14. ((standard or normal or ordinary or guideline or guide line or guideline recommend$ or recommend$ or convention$ or usual or established) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 15. (antihypertensive adj2 (agent$ or drug$ or medicat$)).tw 1 16. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 17.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,637,524 B2 Rao Et Al
    USOO8637524B2 (12) United States Patent (10) Patent No.: US 8,637,524 B2 Rao et al. (45) Date of Patent: Jan. 28, 2014 (54) PYRIMIDINONE INHIBITORS OF Tonn, Biological Mass Spectrometry vol. 22 Issue 11, pp. 633-642 LIPOPROTEIN-ASSOCATED (1993).* PHOSPHOLPASE A2 Hist Biomedical Spectrometry vol. 9 Issue 7, pp. 269-277 Wolen, Journal of Clinical Pharmacology 1986; 26: 419-424.* (75) Inventors: Tadimeti Rao, San Diego, CA (US); Browne, Journal of Clinical Pharmacology 1998; 38: 213-220.* Chengzhi Zhang, San Diego, CA (US) Baillie, Pharmacology Rev. 1981: 33:81-132.* Gouyette, Biomedical and Environmental Mass Spectrometry, vol. (73) Assignee: Auspex Pharmaceuticals, Inc, La Jolla, 15, 243-247 (1988).* CA (US) Cherrah, Biomedical and Environmental Mass Spectrometry vol. 14 Issue 11, pp. 653-657 (1987).* Pieniaszek, J. Clin Pharmacol. 1999; 39: 817-825.* (*) Notice: Subject to any disclaimer, the term of this Honma et al., Drug Metab Dispos 15 (4): 551 (1987).* patent is extended or adjusted under 35 Kushner, D. Jet al., Pharmacological uses and perspectives of heavy U.S.C. 154(b) by 58 days. water and deuterated compounds, Can. J. Physiol. Pharmacol. (1999), 77, 79-88. (21) Appl. No.: 12/840,725 Bauer et al., Influence of long-term infusions on lidocaine kinetics, Clin. Pharmacol. Ther. (1982), 31(4), 433-7. (22) Filed: Jul. 21, 2010 Borgstrom et al., Comparative Pharmacokinetics of Unlabeled and Deuterium-Labeled Terbutaline: Demonstration of a Small Isotope Effect, J Pharm. Sci., (1988), 77(11) 952-4. (65) Prior Publication Data Browne et al., Chapter 2. Isotope Effect: Implications for pharma US 2011/0306552 A1 Dec.
    [Show full text]
  • Pharmacotherapy for Mild Hypertension (Review) – the Cochrane Collaboration
    Pharmacotherapy for mild hypertension (Review) Diao D, Wright JM, Cundiff DK, Gueyffier F This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2012, Issue 11 http://www.thecochranelibrary.com Pharmacotherapy for mild hypertension (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. T A B L E O F C O N T E N T S HEADER ....................................... 1 ABSTRACT ...................................... 1 PLAIN LANGUAGE SUMMARY .............................. 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . 2 BACKGROUND .................................... 5 OBJECTIVES ..................................... 5 METHODS ...................................... 5 RESULTS ....................................... 6 Figure 1. ..................................... 7 DISCUSSION ..................................... 8 Figure 2. ..................................... 9 AUTHORS’ CONCLUSIONS ............................... 10 ACKNOWLEDGEMENTS ................................ 10 REFERENCES ..................................... 10 CHARACTERISTICS OF STUDIES ............................. 13 DATA AND ANALYSES .................................. 19 Analysis 1.1. Comparison 1 Treatment versus No Treatment, Outcome 1 Mortality. 19 Analysis 1.2. Comparison 1 Treatment versus No Treatment, Outcome 2 Stroke. 20 Analysis 1.3. Comparison 1 Treatment versus No Treatment, Outcome 3 Coronary Heart Disease. 20 Analysis 1.4. Comparison 1 Treatment versus
    [Show full text]
  • Cochrane Library
    Cochrane Library Cochrane Database of Systematic Reviews Withdrawal of antihypertensive drugs in older people (Review) Reeve E, Jordan V, Thompson W, Sawan M, Todd A, Gammie TM, Hopper I, Hilmer SN, Gnjidic D Reeve E, Jordan V, Thompson W, Sawan M, Todd A, Gammie TM, Hopper I, Hilmer SN, Gnjidic D. Withdrawal of antihypertensive drugs in older people. Cochrane Database of Systematic Reviews 2020, Issue 6. Art. No.: CD012572. DOI: 10.1002/14651858.CD012572.pub2. www.cochranelibrary.com Withdrawal of antihypertensive drugs in older people (Review) Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Cochrane Trusted evidence. Informed decisions. Library Better health. Cochrane Database of Systematic Reviews T A B L E O F C O N T E N T S HEADER......................................................................................................................................................................................................... 1 ABSTRACT..................................................................................................................................................................................................... 1 PLAIN LANGUAGE SUMMARY....................................................................................................................................................................... 2 SUMMARY OF FINDINGS.............................................................................................................................................................................
    [Show full text]
  • The Pharmacological Treatment of Arterial Hypertension in Frail, Older Patients a Systematic Review
    MEDICINE Original Article The Pharmacological Treatment of Arterial Hypertension in Frail, Older Patients A Systematic Review Viktoria Mühlbauer*, Dhayana Dallmeier*, Simone Brefka, Claudia Bollig, Sebastian Voigt-Radloff, Michael Denkinger he current recommendations for blood pressure tar- Summary get values and pharmacological treatment of arterial hypertension in older people are heterogeneous (1, Background: It is debated whether the treatment goals and decision-making T 2). The 2017 guideline of the American College of Car- algorithms for elderly patients with hypertension should be the same as those for diology recommends a new target value of systolic blood younger patients. The American and European guidelines leave decisions about pressure <130 mmHg for persons ≥ 65 years living at antihypertensive treatment in frail, institutionalized patients up to the treating home (3). For the same age group, the recently published physician. We therefore systematically searched the literature for publications on guidelines of the European Society of Cardiology (ESC), the phamacotherapy of arterial hypertension in frail patients. state a target range of 130 to 139 mmHg for systolic Methods: The MEDLINE, Embase, and Central databases were systematically pressure (level of evidence A) (4). The German Hyperten- searched for randomized, controlled trials (RCTs) and non-randomized studies, sion League and the German College of General including observational studies, on the pharmacotherapy of arterial hypertension in Practitioners and Family Physicians (DEGAM) also elderly patients since the introduction of the concept of frailty, published over the recommend that the blood pressure should be period 1992–2017. <140/90 mmHg in the elderly (5–7). However, the Results: Out of 19 282 citations for randomized, controlled trials and 5659 for DEGAM describes the research data on antihypertensive non-randomized trials and observational studies, four RCTs and three observational treatment in older patients as inadequate (6).
    [Show full text]